Posts Tagged ‘drug development’



Compound- to Target-Centric: A New View of Drug Discovery with H3 Biomedicine CEO Markus Warmuth

October 29th, 2012
Posted by

The cost and risk associated with biopharmaceutical R&D is enormous and the rewards are increasingly elusive. For many young firms, the “valley of death” is a very real obstacle. What can startups (and larger companies) do? In the first blog post based on my interview with H3 Biomedicine CEO Markus Warmuth, we discussed H3’s strategy to propel innovative therapies into the market using a tighter time frame based upon a new research and clinical paradigm that is almost the reverse of traditional biopharmaceutical development. In this segment, Warmuth shares with us some specifics about H3 Biomedicine’s unique approach to drug development.
 

Q: What is the current approach to drug discovery at H3?
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | No Comments »





Drug Development Gets Even More Personal, Precise and Tailored

March 27th, 2012
Posted by

As we’ve discussed, Eric Topol’s “How to Change Medicine” provides valuable insights on how tailoring treatments in the clinic could boost health care effectiveness and lower costs. But we at Popper and Company would like to see industry take an additional step by using the techniques Dr. Topol recommends for patient care to develop drugs more efficiently.
 
The technology Topol recommends to stratify patients could also streamline drug development. In fact, the FDA is suggesting that faster approvals of antibiotics could result from smaller clinical trials that test antibiotics targeted against drug-resistant bacteria.
 
We now know enough about molecular biology that we can apply genomics/proteomics/metabolomics to drug development (DNA screening, identifying and validating surrogate markers, or characterizing tumors by genetic makeup). However, tailored treatments can run into challenges, including  heterogeneity in tumor cells as recently described in the New England Journal of Medicine, that resist even targeted biological treatments.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | No Comments »





Applauding Cautious Optimism from a Big Pharma CEO

December 1st, 2011
Posted by

Recently journalists at WSJ and Xconomy interviewed John Lechleiter, Chairman, President & CEO, of Eli Lilly and Company. When I sat down to read Mr. Lechleiter’s interviews, I was prepared to get up from my desk several times to find something more interesting to do thinking the articles were to be somewhat mind-numbing. My expectations were not based on any preconceived notions about Mr. Lechleiter, but rather that I assumed the focus of the interviews would be lamenting the pharmaceutical industry’s problems. Instead I was encouraged by Lechleiter’s dedication and optimism.
 
It is increasingly easy to criticize big pharma: Fewer truly “new” drugs are developed. It is difficult to understand the economics behind the high costs of certain drugs. After being approved, some drugs go on to be proven ineffective or, sometimes, potentially dangerous.
  Read the rest of this entry »

Tags: , , , , , , , ,
Posted in Our Views | No Comments »